Vir Biotechnology (VIR) Non-Current Deferred Tax Liability (2018 - 2023)

Vir Biotechnology (VIR) has 6 years of Non-Current Deferred Tax Liability data on file, last reported at $3.3 million in Q1 2023.

• For the quarter ending Q1 2023, Non-Current Deferred Tax Liability fell 82.36% year-over-year to $3.3 million; the trailing twelve-month figure through Mar 2023 stood at $3.3 million (down 82.36% YoY), and the FY2022 full-year result was $3.3 million, down 82.36% from the prior year.
• Non-Current Deferred Tax Liability held at $3.3 million in Q1 2023, from $3.3 million in the prior quarter.
• In the past five years, Non-Current Deferred Tax Liability ranged from a high of $18.4 million in Q4 2021 to a low of $3.3 million in Q4 2020.
• A 5-year average of $7.3 million and a median of $3.3 million in 2019 frame the typical range for Non-Current Deferred Tax Liability.
• Across the five-year window, Non-Current Deferred Tax Liability surged 466.83% in 2021 and slumped 82.36% in 2022, its largest moves.
• Tracing VIR's Non-Current Deferred Tax Liability over 5 years: stood at $3.3 million in 2019, then decreased by 1.57% to $3.3 million in 2020, then surged by 466.83% to $18.4 million in 2021, then tumbled by 82.36% to $3.3 million in 2022, then changed by 0.0% to $3.3 million in 2023.
• Business Quant data shows VIR's Non-Current Deferred Tax Liability at $3.3 million in Q1 2023, $3.3 million in Q4 2022, and $18.4 million in Q3 2022.